A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Latest Information Update: 07 Jun 2025
At a glance
- Drugs BG 68501 (Primary) ; BGB-43395 (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 02 Jun 2025 According to a BeOne Medicines Media Release, initial results from this trial has been presented in the ASCO 2025.
- 02 Jun 2025 Results presented in the BeOne Medicines Media Release.
- 27 May 2025 According to BeOne Medicines media release, BeiGene is now called BeOne Medicines